categorized based on AUC as having either high accuracy (0.9-1.0), moderate accuracy (0.7-0.9), or poor accuracy (0.5-0.7), as suggested by Swets [3] . In the 250-8000 Hz audiometric hearing loss validation cohort and the clinically determined hearing loss validation cohort, the AUCs were 0.69 and 0.60, respectively, which indicated poor accuracy. There are some other models that have been developed for hearing loss prediction, which showed satisfied accuracy. Johnson et al [4] built a model for predicting hearing loss in patients receiving cisplatin chemotherapy, in which the AUCs were 0.842 (common subjects) and 0.91 (subjects who received concurrent head and neck irradiation). Sanders et al [5] added toll-like receptor (TLR)9-1237 single nucleotide polymorphisms (SNPs) and combined TLR2 + 2477 and TLR4 + 896 SNPs in a prediction for postmeningitis hearing loss in childhood where the AUCs were 0.861 and 0.875, respectively.
Third, the authors tried to identify patients with DR-TB who were at the highest risk of developing AG-induced ototoxicity and to help prioritize patients for AG-sparing regimens in clinical settings. We think a decision curve analysis (DCA) is necessary for this prediction model. DCA is a method for evaluating the benefits of a prediction model across a range of patient preferences for accepting the risks of undertreatment and overtreatment, to facilitate decisions about test selection and use [6] . DCA has some advantages compared with the traditional receiver operating characteristic curve (ROC Reply to Chen, Song, and Liu
To the Editor-Chen and colleagues [1] suggest that our prediction model of hearing loss among patients receiving aminoglycosides for the treatment of multidrug-resistant tuberculosis (MDR-TB) [2] should undergo validation in other cohorts, achieve a higher level of accuracy, and undergo additional analyses prior to clinical application. We agree with this assessment, but would like to clarify these concerns further.
First, we acknowledge that ultrahighfrequency audiometry is more clinically useful for the early detection of ototoxicity because typical manifestations of cochleotoxicity begin with ultrahighfrequency hearing loss and are often undetected by standard audiometry testing [3, 4] . However, due to the small sample size of ultrahigh-frequency data in our patient sample, we were unable to develop a prediction model specifically for ultrahighfrequency hearing loss. We do feel that validation of our prediction model for ultrahigh-frequency hearing loss provides important ancillary data indicating that our model performs reasonably well in detecting this form of hearing loss. But we acknowledge that there is a need for external validation and refinement of the prediction model to achieve better generalizability and practicality using both regular-and ultrahigh-frequency audiometric data. As Chen and colleagues [1] suggest, external validation would ideally use different population sets; this is an important direction for future research.
With respect to accuracy, we agree that an area under the curve (AUC) of 0.69 does not suggest high predictive accuracy, but would argue against an arbitrary cutoff of 0.7 for "moderate" versus "poor" predictive accuracy. Especially in contexts such as MDR-TB treatment in sub-Saharan Africa-characterized by extreme limitations of both data and resourceseven modest predictive accuracy can add important value. Furthermore, the AUC is a global measure, whereas the clinical value of a prediction rule is better described by the sensitivity and specificity of specific cutoffs that might be used. Specifically, as below (and as argued in the original publication), we believe our prediction rule can be useful in identifying patients with high predicted probabilities of hearing loss.
Finally, in response to the helpful recommendation by Chen and colleagues [1] , we performed a decision curve analysis to further evaluate the clinical utility of our prediction rule. The decision curve shows that the prediction model adds net benefit when using a threshold probability of 50% or higher to identify patients who might qualify for aminoglycoside-sparing regimens when access to those regimens is limited (Figure 1 
